Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
egfrviii car-pbl
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EGFRvIII CAR-PBL is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by the National Cancer Institute (NCI) Surgery Branch. It consists of a patient's own peripheral blood lymphocytes (PBLs) that are genetically engineered ex vivo using a retroviral vector to express a CAR specific for the EGFRvIII mutation. EGFRvIII is a tumor-specific variant of the epidermal growth factor receptor frequently expressed in malignant gliomas but absent in normal tissues, making it an ideal target for immunotherapy. The CAR construct includes a signaling domain (typically CD28 and CD3-zeta) to trigger T-cell activation upon binding to the target antigen. This therapy has been evaluated in Phase I/II clinical trials for patients with EGFRvIII-positive glioblastoma and gliosarcoma, administered intravenously following lymphodepleting chemotherapy and alongside aldesleukin (IL-2).
- Other names
- Anti-EGFRvIII CARAnti-EGFRvIII CAR-transduced PBLAnti-EGFRvIII CAR, PG13-139-CD8-CD28BBZ (F10) transduced PBL
02
Targets
EGFRvIII (Epidermal growth factor receptor variant III)
Beyond the preview
Go deeper on egfrviii car-pbl.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on egfrviii car-pbl.